Probiotic neoantigen delivery vectors for precision cancer immunotherapy.

ABSTRACT: Microbial systems have been synthetically engineered to deploy therapeutic payloads in vivo^1,2. With emerging evidence that bacteria naturally home in on tumours^3,4 and modulate antitumour immunity^5,6, one promising application is the development of bacterial vectors as precision cancer vaccines^2,7. Here we engineered probiotic Escherichia coli Nissle 1917 as an antitumour vaccination platform optimized for enhanced production and cytosolic delivery of neoepitope-containing peptide arrays, with increased susceptibility to blood clearance and phagocytosis. These features enhance both safety and immunogenicity, achieving a system that drives potent and specific T cell-mediated anticancer immunity that effectively controls or eliminates tumour growt

SUBMITTER: Redenti A 

PROVIDER: S-EPMC11560847 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature